Interaction of doxorubicin with the subcellular structures of the sensitive and Bcl-xL-overexpressing MCF-7 cell line: Confocal and low-energy-loss transmission electron microscopy

Micron

Volumn 40, Issue 7, 2009, Pages 702-712

  Mhawi, A Amir ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Bcl xL; Doxorubicin; Electron energy loss; Electron microscopy; MCF 7; Microanalysis

Indexed keywords

ANTI-CANCER AGENTS; BCL-XL; CELL TYPES; CELLULAR COMPARTMENTS; CELLULAR EVENTS; CONFOCAL MICROSCOPES; DOXORUBICIN; ELECTRON ENERGY LOSS; ENERGY FILTER; ENERGY LOSS; ENERGY RESOLUTIONS; INCUBATION TIME; LOW ENERGIES; MCF-7; MCF-7 CELLS; NUCLEAR MEMBRANES; ORBITAL EXCITATIONS; OVER-EXPRESSION; SUBCELLULAR COMPARTMENTS; SUBCELLULAR STRUCTURE; THIN SECTION; ULTRASTRUCTURAL LOCALIZATION;

CELL CULTURE; DISSOCIATION; DRUG INTERACTIONS; ELECTRON ENERGY LEVELS; ELECTRON ENERGY LOSS SPECTROSCOPY; ELECTRON MICROSCOPES; ELECTRONS; ENERGY DISSIPATION; HEAVY METALS; MICROANALYSIS; MITOCHONDRIA; MOLECULAR ORBITALS; NUCLEAR INSTRUMENTATION; TRANSMISSION ELECTRON MICROSCOPY;

CELL MEMBRANES;

ANTINEOPLASTIC ANTIBIOTIC; BCL2L1 PROTEIN, HUMAN; DOXORUBICIN; FLUORESCENT DYE; ORGANIC COMPOUND; PROTEIN BCL X; RED DYE CMXROS;

ARTICLE; BIOSYNTHESIS; CELL LINE; CELL NUCLEUS MEMBRANE; CONFOCAL MICROSCOPY; DRUG EFFECT; HUMAN; MITOCHONDRION; NUCLEOLUS; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; BCL-X PROTEIN; CELL LINE; CELL NUCLEOLUS; DOXORUBICIN; FLUORESCENT DYES; HUMANS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; NUCLEAR ENVELOPE; ORGANIC CHEMICALS; UP-REGULATION;

EID: 67649654108     PISSN: 09684328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micron.2009.05.005     Document Type: Article

References (42)

1. Abe T., Fukamachi Y., Kanazawa Y., Furukawa H., Shimizu K., Hirano T., Kasai H., Kashimura M., and Higashi K. Inhibition of nucleolar function and morphological change by adriamycin associated with heat shock protein 70 accumulation. Jpn. J. Cancer Res. 87 (1996) 945-951
2. Altan N., Chen Y., Schindler M., and Simon S.M. Defective acidification in human breast tumor cells and implications for chemotherapy. J. Exp. Med. 187 (1998) 1583-1598
3. Anderson A.B., and Arriaga E.A. Subcellular metabolite profiles of the parent CCRF-CEM and the derived CEM/C2 cell lines after treatment with doxorubicin. J. Chromatogr. B 808 (2004) 295-302
4. Arancia G., Bordi F., Calcabrini A., Diociaiuti M., and Molinari A. Ultrastructural and spectroscopic methods in the study of anthracycline-membrane interaction. Pharmacol. Res. 32 (1995) 255-272
5. Barfels M.M.G., Jiang X.G., Heng Y.M., Arsenault A.L., and Ottensmeyer F.P. Low-energy-loss electron microscopy of chromophores. Micron 29 (1998) 97-104
6. Berthiaume J.M., and Wallace K.B. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 23 (2007) 15-25
7. Binaschi M., Bigioni M., Cipollone A., Rossi C., Goso C., Maggi C.A., Capranico G., and Animati F. Anthracyclines: selected new developments. Curr. Med. Chem. Anticancer Agents 1 (2001) 113-130
8. Bobichon H., Cailleret L., Ploton D., Belhoussine R., and Jardillier J.C. Nuclear transport as an ultimate step of multidrug resistance. Life Sci. 65 (1999) 2343-2349
9. Bour-Dill C., Gramain M., Merlin J., Marchal S., and Guillemin F. Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis. Cytometry 39 (2000) 16-25
10. Box V.G. The intercalation of DNA double helices with doxorubicin and nogalamycin. J. Mol. Graph Model 26 (2007) 14-19
11. D'Arpa P., and Liu F.L. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta 989 (1989) 163-177
12. Davis J.A., Heag Y.M., Barfels M.M., Bisland S.K., Gariepy J., and Ottensmeyer F.P. Localization of chromophore absorption signals in TEM with an improved prism-mirror-prism filter. J. Electron Microsc. (Tokyo) 49 (2000) 629-639
13. De Oliveira F., Chauvin C., Ronot X., Mousseau M., Leverve X., and Fontaine E. Effects of permeability transition inhibition and decrease in cytochrome c content on doxorubicin toxicity in K562 cells. Oncogene 25 (2006) 2646-2655
14. Featherstone J.M., Speers A.G., Lwaleed B.A., Hayes M.C., Cooper A.J., and Birch B.R. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines. BJU Int. 95 (2005) 1091-1098
15. Fiebig A.A., Zhu W., Hollerbach C., Leber B., and Andrews D.W. Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer 6 (2006) 213
16. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57 (1999) 727-741
17. Gnanapragasam A., Yogeeta S., Subhashini R., Ebenezar K.K., Sathish V., and Devaki T. Adriamycin induced myocardial failure in rats: protective role of centella asiatica. Mol. Cell. Biochem. 294 (2007) 55-63
18. Gong Y., Wang Y., Chen F., Han J., Miao J., Shao N., Fang Z., and Yang R.O. Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line. Leukemia Res. 24 (2000) 769-774
19. Iwasaki T., and Suzuki T. Ultrastructural alterations of the myocardium induced by doxorubicin. A scanning electron microscopic study. Virchows Arch. B: Cell Pathol. Incl. Mol. Pathol. 60 (1991) 35-39
20. Jiang X.G., and Ottensmeyer F.P. Optimization of a prism-mirror-prism imaging energy filter for high resolution electron microanalysis. Optik 94 (1993) 88-95
21. Jung K., and Reszka R. Mitochondria as subcellular targets for clinically useful anthracyclines. Adv. Drug Deliv. Rev. 49 (2001) 87-105
22. Karnovsky M.J. A formaldehyde-glutaraldehyde fixative of high osmolality for use in electron microscopy. J. Cell Biol. 27 (1965) 137A-138A
23. Kiyomiya K., Matsuo S., and Kurebe M. Proteasome is a carrier to translocate doxorubicin from cytoplasm into nucleus. Life Sci. 62 (1998) 1853-1860
24. Kiyomiya K., Matsuo S., and Kurebe M. Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex. Cancer Res. 61 (2001) 2467-2471
25. L'Ecuyer T., Sanjeev S., Thmas R., Novak R., Das L., Campbell W., and Heide R.V. DNA damage is an early vent in doxorubicin-induced cardiac myocyte death. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H1273-H1280
26. Merski J.A., Daskal I., and Bush H. Effects of adriamycin on ultrastructure of nucleoli in the heart and liver cells of the rat. Cancer Res. 36 (1976) 1580-1584
27. Mhawi A.A., Fernandes A.B., and Ottensmeyer F.P. Low-energy-loss electron microscopy of doxorubicin in human breast cancer MCF-7 cells: localization by color. J. Struct. Biol. 158 (2007) 80-92
28. L can confer a multidrug resistance phenotype. Blood 86 (1995) 1903-1910
29. Mizutani H., Oikawa S., Hiraku Y., Murata M., Kojima M., and Kawanishi S. Distinct mechanisms of site-specific oxidative DNA damage by doxorubicin in the presence of copper (II) and NADPH-cytochrome P450 reductase. Cancer Sci. 94 (2003) 686-691
30. Munteanu E., Verdier M., Grandjean-Forestier F., Stenger C., Jayat-Vignoles C., Huet S., Robert J., and Ratinaud M. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Biochem. Pharmacol. 71 (2006) 1162-1174
31. Newman G.R. LR White embedding medium for colloidal gold methods. In: Hayat M.A. (Ed). Colloidal Gold: Principles, Methods, and Applications vol. 2 (1989), Academic Press, San Diego 47-73
32. O'Neill J., Manion M., Schwartz P., and Hockenbery D.M. Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy. Biochim. Biophys. Acta 1705 (2004) 43-51
33. Parra V., Eisner V., Chiong M., Criollo A., Moraga F., Garcia A., Hartel S., Jaimovich E., Zorzano A., Hidalgo C., and Lavandero S. Changes in mitochondrial dynamics during ceramide-induced cardiomyocyte early apoptosis. Cardiovasc. Res. 77 (2008) 387-397
34. Rajagopal A., and Simon S.M. Subcellular localization and activity of multidrug resistance proteins. Mol. Biol. Cell 14 (2003) 3389-3399
35. Reeve J.L., Szegezdi E., Logue S.E., Chonghaile T.N., O'Brien T., Ritter T., and Samali A. Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-xL. J. Cell Mol. Med. 11 (2007) 509-520
36. Sardão V.A., Oliveira P.J., Holy J., Oliveira C.R., and Wallace K.B. Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell Biol. Toxicol. 25 (2009) 227-243
37. Siegfried J.M., Burke T.G., and Tritton T.R. Cellular transport of anthracyclines by passive diffusion. Biochem. Pharmacol. 34 (1985) 593-598
38. Skovsgaard T. Transport and binding of daunoruvbicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. Biochem. Pharmacol. 26 (1977) 215-222
39. Solem L.E., Henry T.R., and Wallace K.B. Disruption of mitochondrial calcium homoeostasis following chronic doxorubicin administration. Toxicol. Appl. Pharmacol. 129 (1994) 214-222
40. Speelmans G., Staffhorst R.W., Steenbergen H.G., and deKruijff B. Transport of the anti-cancer drug doxorubicin across cytoplasmic membrane and membrane composed of phospholipids derived from Escherichia coli occurs via similar mechanism. Biochim. Biophys. Acta 1284 (1996) 240-246
41. L regulates the membrane potential and volume homeostasis of mitochondria. Cell 91 (1997) 627-637
42. Yung B.Y., Chang F.J., and Luo K.J. Dipyridamole enhancement of doxorubicin-induced translocation of nucleophosmin and inhibition of cell growth in HL-60 cells. Int. J. Cancer 21 (1991) 592-597